Condition

Refractory Acute Lymphoblastic Leukemia

ClinicalTrials.gov condition label

Clinical trials2

Recruiting0

Common interventions25

Lead sponsors shown2

Clinical trials

2 shown

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialNCT03878524 · 2020-04-01

TERMINATED

Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or LymphomaNCT03096782 · 2017-10-13

COMPLETED

Common interventions

AbemaciclibDRUG1AbirateroneDRUG1AfatinibDRUG1Anti-Thymocyte GlobulinBIOLOGICAL1BevacizumabBIOLOGICAL1BicalutamideDRUG1Biospecimen CollectionPROCEDURE1BortezomibDRUG1BusulfanDRUG1CabazitaxelDRUG1CabozantinibDRUG1CapecitabineDRUG1CarboplatinDRUG1CelecoxibDRUG1ClofarabineDRUG1CobimetinibDRUG1CopanlisibDRUG1CyclophosphamideDRUG1DabrafenibDRUG1DacomitinibDRUG1DarolutamideDRUG1DasatinibDRUG1DoxorubicinDRUG1DurvalumabBIOLOGICAL1EnasidenibDRUG1

Leading sponsors

M.D. Anderson Cancer Center1OHSU Knight Cancer Institute1

Trial status mix

COMPLETED1

TERMINATED1

Phase mix

PHASE11

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.